Compare AI & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AI | ORIC |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2020 | 2020 |
| Metric | AI | ORIC |
|---|---|---|
| Price | $10.79 | $12.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | $14.00 | ★ $19.73 |
| AVG Volume (30 Days) | ★ 5.0M | 1.0M |
| Earning Date | 05-27-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $250,268,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.68 | $7.23 |
| 52 Week High | $20.22 | $14.93 |
| Indicator | AI | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 63.89 | 48.56 |
| Support Level | $9.73 | $10.67 |
| Resistance Level | $11.94 | $14.27 |
| Average True Range (ATR) | 0.50 | 0.59 |
| MACD | 0.02 | -0.21 |
| Stochastic Oscillator | 89.18 | 33.05 |
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions, namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications; C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications; and C3 Generative AI, which combines the utility of large language models. Geographically, the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.